Valeant’s Debt Problems Continue to Be Overhangs for the Stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were stumbling almost 6%, having lost practically 13% …
Cantor analyst Louise Chen had the opportunity to discuss this morning with Valeant Pharmaceuticals Intl Inc (NYSE:VRX) management regarding some concern that formulary changes …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced the launch of SILIQ™ (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in …
Controversial drug-maker Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is due to report its Q2 results on August 8. The Street is forecasting EPS of …
Valeant on Track to Meet $5 Billion Debt Reduction Commitments Ahead of Goal In a bullish research note previewing second quarter earnings from …
Tesla’s CEO Shakes Investor Confidence Tesla Inc (NASDAQ:TSLA) CEO Elon Musk is downplaying his brainchild, telling an audience at the National Governors Association …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is putting more efforts to repay the term loan debt under its Senior Secured Credit Facility. This morning, the …
Valeant’s Siliq Not Competitive Enough in Psoriasis Market Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) fighting chances in the drug arena to compete may have just …
Don’t Overvalue Valeant’s Recent Rally, Teva’s Momentum Waiting in Back Half of the Year
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares slightly rose in Thursday’s trading session, after the drug maker announced that it is redeeming approx. $500 million …
